

## Moerae Matrix Inc.

Moerae Matrix, Inc., is developing novel, locally-active peptide therapeutics — drugs that mimic or block active portions of proteins naturally produced by the body to mediate key biologic functions.

Four compounds, now in the preclinical stage, have been generated from Moerae Matrix' discovery platform. These drugs will be developed for high-value market applications that include cosmetic and general surgery as well as oncology.



The company's novel-target drugs are designed to yield ideal properties for agents within the peptide therapeutics class. The drugs have cell-penetrating domains, which confer both ability to impact intracellular processes as well as rapid drug uptake by target cells, with minimal systemic distribution following local delivery.

Moerae Matrix' drugs may be administered alone or coupled to a proprietary hydrogel matrix, allowing drug release over hours, days, weeks or months (and thus extended interinjection intervals). Release from the matrix may be stimulated by time, temperature or pH, as required by specific applications. Moerae Matrix has licensed intellectual property protecting the unique technology and its applications from Purdue Research Foundation (drugs) and inventors (hydrogel matrix).

The company's technology is based on the pioneering work of scientific founder Alyssa Panitch, Ph.D., associate professor, and colleague Brandon Seal, Ph.D., assistant professor, at Purdue University's Weldon School of Biomedical Engineering. Colleen Brophy, Ph.D., professor of surgery at Vanderbilt University, recently has agreed to collaborate with Drs. Panitch and Seal in Moerae Matrix. Drs. Panitch and Brophy have been continuously funded throughout their academic careers by the National Institutes of Health (NIH) and the Veterans Affairs Medical Center, and have received numerous awards for excellence in research.

A commercialization team comprises the company's scientific founder and its commercial partner Nascent Enterprises, which is a company associated with the creation of 21 life sciences ventures based on innovative medical technologies.



Cynthia Lander



Alyssa Panitch

### Facts & Figures

**ESTABLISHED:** 2007 — Founded by Alyssa Panitch, Purdue University Associate Professor of Biomedical Engineering; and Cynthia Lander

**KEY PERSONNEL:** Cynthia Lander, Ph.D., President and CEO; Alyssa Panitch, Ph.D., Chief Scientific Officer; and Tony Dimun, Chairman and CFO

**CONTACT:** Purdue Technology Center, Purdue Research Park, 3000 Kent Ave., West Lafayette, IN, 47906; (973) 632-0283; clander@moeraematrix.com